Arrowhead Research

ARWR

Market cap $9.15B

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462. This sale represented 2.17% of Mr.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli.

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Arrowhead Pharmaceuticals, Inc. shares rose on early data from obesity candidates ARO-INHBE and ARO-ALK7, but I have more questions than answers. INHBE-targeted monotherapy is unlikely to drive meaningful weight loss. Combination data with tirzepatide showed promising weight loss, but tiny sample sizes and missing datasets raise concerns about the true efficacy.

Arrowhead's experimental therapy helped patients on Lilly's Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.

Arrowhead, Inc. (NASDAQ: ARWR) on Tuesday shared interim results from two Phase 1/2a trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics for obesity.

Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.